In specialised cells, the expression of specific isoforms of tubulin and their subsequent post-translational modifications are thought to drive and co-ordinate unique morphologies and behaviours. The mechanisms by which -1 tubulin (encoded by TUBB1), the platelet and megakaryocyte lineage restrictedtubulin isoform, drives these processes remains poorly understood. We investigate the effects of two key tubulin posttranslational polymodifications (polyglutamylation and polyglycylation) on the glutamate rich C-terminus of -1 tubulin using a cohort of thrombocytopenic patients, human induced pluripotent stem cell (iPSC) derived megakaryocytes, and healthy human donor platelets. We find that while megakaryocytes (MKs) are positive for both polymodifications, polyglycylation is substantially reduced on platelets. On platelet activation, the marginal band becomes heavily polyglutamylated, which drives the mobilisation of motor proteins, including axonemal dynein, to achieve the shape change required for the haemostatic role of platelets. We show that a number of modifying enzymes (Tubulin Tyrosine Like Ligases (TTLLs) and Cytosolic Carboxypeptidases (CCPs)) are up-regulated during MK maturation. We find that in platelets, a single polyglutamylase (TTLL7) is expressed to mediate the polyglutamylation of the marginal band required for shape change on activation. Finally, we report a novel disease causing gene defect in multiple families (TTLL10) resulting in bleeding despite normal platelet production and function. This work highlights the importance of a complex regulatory mechanism driven by both cell specific tubulin isoform expression and differential post-translational modification to drive specialist function, the loss of which results in disease states. 
Introduction
Microtubules are large, cytoskeletal filaments vital to a host of critical functions including cell division, signalling, cargo transport, motility, and function(1-3). Despite their ubiquitous expression and high structural conservation, microtubules also drive unique morphologies and functions in specialist cell types like ciliated cells, spermatozoa, and neurons (4, 5) . The question of how filaments expressed in every cell in the body can facilitate complex and highly unique behaviours like neurotransmitter release and retinal organisation has been addressed by the tubulin code. This is a paradigm which accounts for the specialisation of microtubules and their organisation by describing a mechanism in which particular cells express lineage restricted isoforms of tubulin. These cell specific isoforms are then subject to a series of post-translational modifications which alter the mechanical properties of microtubules, and their capacity to recruit accessory proteins (e.g. motors)(1-3, 5). A host of tubulin post-translational modifications (PTMs) have been reported in a range of cell types, including (but not limited to) tyrosination, acetylation, glutamylation, glycylation, and phosphorylation. In recent years links between the loss of specific tubulin PTMs, either through the aberrant expression of tubulin isoforms or the loss of effecting or reversing enzymes, has emerged (5) . The loss of posttranslationally modified tubulin has been reported to impact motile and non-motile ciliary function (including respiratory cilia, retinal cells), spermatogenesis, muscular disorders, and neurological development and function(1, 5-11).
Of the many cell systems in which careful regulation of tubulin modification is required for healthy function, the role of the tubulin code in the generation of blood platelets from their progenitors, megakaryocytes (MKs) remains relatively poorly understood. Platelets are the smallest component of peripheral blood, and circulate as anucleate cells with an archetypal discoid shape maintained by a microtubule marginal band (12, 13) . The activation of platelets involves a tightly regulated rearrangement of the cytoskeleton which results in a series of shape changes (13) (14) (15) . Antagonistic motor proteins maintain the resting state of the marginal band, and during platelet activation a motor protein dependent mechanism results in sliding which extends the marginal band and causes the transition to a spherical shape (13, 14) . The disc-to-sphere transition is a critical part of platelet activation, which also involves the secretion of granules as a terminal step in platelet activation. Conversely megakaryocytes are the largest and rarest haematopoeitic cell of the bone marrow. These cells are characteristically large, polyploid cells with unique morphological structures (e.g. the invaginated membrane system (IMS)) required to facilitate the production of thousands of blood platelets and package within them the required prothrombotic factors (16) . Extensive cytoskeletal remodelling is critical to the maturation of MKs and the maintenance of key structures like IMS, as well as to the production of platelets themselves (15, 16) . MKs form long, beaded extensions into the lumen of bone marrow sinusoids -where these proplatelet extensions then experience fission under the flow of sinusoidal blood vessels which results in the release of barbell shaped pre-platelets and platelets into the blood stream (16) . Both MKs and platelets express a lineage restricted isoform of -tubulin (-1 tubulin) encoded by the gene TUBB1 (17) . In humans, TUBB1 mutations have been shown to result in impaired platelet production, with a resulting macrothrombocytopenia (18, 19) . More recently, a Cterminal truncation of -1 tubulin has been shown to cause a macrothrombocytopenia, suggesting that C-terminal modifications may be drivers of protein function and causative of the disease phenotype observed (20) . While the loss of TUBB1 is known to result in macrothrombocytopenia, the mechanisms by which this isoform of tubulin effects the dramatically different cytoskeletal behaviours of platelets and MKs remains poorly understood. In the context of the tubulin code, MKs and platelets present a particularly interesting model. Both cells express a specific -tubulin isoform (-1 encoded by TUBB1), but undergo markedly different cytoskeletal changes. To date, acetylation and tyrosination have been the PTMs primarily reported in MKs and platelets, however neither modification is specific to the C-terminal tail encoded by TUBB1. Fiore et al. show that a C-terminal truncation of TUBB1 phenocopies the complete loss of the protein (13, 21) . We therefore hypothesise that PTMs specific to the C-terminus of TUBB1 are required for the complex morphological rearrangements required for both MK and platelet function. The C-terminal tail of -1 tubulin is particularly rich in glutamate residues which are often targeted for two key post-translational modifications implicated in human disease. Polyglutamylation and glycylation are PTMs which target glutamate residues on both tubulin subunits (-and -) and result in the addition of glutamate or glycine residues respectively(1, 2, 22) . Interestingly polyglutamylation has been observed in microtubules in centrioles, axenomes, neuronal outgrowths, and mitotic spindles(1, 2). Thus far polyglycylation has primarily been observed in axenomes, suggesting a role for polyglycylation and polyglutamylation in regulating ciliary function -with important consequences for ciliopathies(1). As these polymodifications target the same substrate, namely glutamate residues in tubulin tails, it has been suggested that these PTMs are competitive. For example, glutamylation is evident on -tubulin in post-natal development, but is found on --tubulin in younger neurons (23) . There is some debate as to whether these polymodifications negatively regulate one another (24, 25) . Mutations in the glutamylases and deglutamylases regulating polymodification can cause male infertility through aberrant spermatogenesis and poor sperm motility, as well as dysfunctions in airway cilia and axonal transport (9, 11, (26) (27) (28) (29) To date polyglycylation has not been reported in MKs or platelets. Recently Van Dijke et al. report on the polyglutamylation of TUBB1 in a CHO cell line engineered to express TUBB1 downstream of the integrin -2 b -3 , and platelets spread on fibrinogen (30) . However, to effectively study and interpret the effects of post-translationally modified tubulin residues a model is required which recapitulates the complex network of regulatory enzymes effecting and reversing PTMs. This is particularly important in light of potential evolutionary divergences in the function of TTLL enzymes implicated by Rogowski et al. (25) . To interrogate the polymodification of the C-terminal tail of TUBB1 as a driver of both platelet formation and function, we report on two unrelated families with variants in the Cterminal region of TUBB1 gene, resulting in a macrothrombocytopenia and bleeding. Existing cell lines poorly emulate the expression profiles and platelet producing capacity of MKs, therefore to develop a representative model we adapt a directed differentiation protocol to generate a large population of proplatelet forming MKs from induced pluripotent stem cells (iPSCs), and apply these cells to report on the extensive polyglycylation and polyglutamylation of proplatelet forming MKs. We demonstrate that these polymodifications are removed in resting platelets, but that upon activation, platelets undergo a specific polyglutamylation of the marginal band to undergo spreading. We go on to show that on platelet activation, kinesin and dynein poorly co-localise with polyglutamylated residues, supporting previous work which suggests that polylgutamylation impacts motor protein processivity. We therefore reason that polyglutamylation is the mechanism by which platelet marginal bands are destabilised on activation. The role of polyglycylation in platelet activity remains unclear, however we report on patient variants in 3 unrelated families which result in a loss-of-function of the polyglycylase TTLL10, suggesting a role for this gene, previously thought to be non-functional in humans, in platelet production. Finally, we perform a quantitative mRNA-expression analysis of the 13 known mammalian tubulin tyrosin like ligases (TTLLs) and 6 Cytosolic Carboxypeptidases (CCPs) and report an increase in the expression of specific TTLLs and CCPs in maturing and proplatelet forming MKs. Our in vitro work identifies a mechanism by which maturing MKs express a palette of TTLLs and CCPs to reversibly polyglutamylate and polyglycylate -1 tubulin to regulate motor protein motility and drive platelet production. Knocking-out TUBB1 in iPSC-MKs results in a loss of platelet production, and disordered polymodification. In platelets a single polyglutamylase, TTLL7 is expressed to drive the polyglutamylation of the marginal band needed to destabilise this structure for platelet activation and shape change. This study reports on a highly unique mechanism of reversible polymodification which drives the specialist behaviours of both platelets and their progenitors, MKs.
Results
Identification and initial characterisation of TUBB1 variants in patients with inherited thrombocytopenia and platelet dysfunction. Using whole exome sequencing, two C-terminal TUBB1 variants were identified in patients from the GAPP cohort, affected individuals in unrelated families presenting with macrothrombocytopenia (Figure 1 A) . Affected indivudals in Family A were found to be heterozygous for a C>T transition resulting in an arginine to tryptophan amino acid substitution (c.C1075T, p.R359W) in TUBB1. Individuals in this family also carry a GFI1B variant (p.Cys168Phe). Variants in both genes have been linked to thrombocytopenia, however only individuals A:1 and A:3, both of whom carry TUBB1 variants, present with a macrothrombocytopenia (107 and 85 x 10 9 /L respectively). Individual A:2 carries the GFI1B variant but is wild type for TUBB1 and presents with a normal platelet count (221 x 10 9 /L). This shows that the TUBB1 variant is responsible for the macrothrombocytopenia, and not GFI1B. Interestingly, individuals A:1 and A:3 also present with significantly higher immature platelet fractions (IPFs) and mean platelet volumes (MPVs) than their TUBB1 WT relative (53.5% and 55.1% compared to 25.5%, MPV for A:1 and A:3 too large for measurement). This variation in count and phenotype suggest that TUBB1 is causative of the macrothrombocytopenia observed. Family/patient B was an elderly gentleman (now deceased) with a G insertion and subsequent frameshift truncation of the protein 19 amino acids from the site of insertion (c.1080insG, p.L:361Afs*19). This patient had a severe macrothrombocytopenia with a platelet count of 11 x 10 9 /L and an MPV above 13.4 ( Figure 1B) . At the time of study, IPF measurement was unavailable. Both TUBB1 variants are positioned in the C-terminal region of the -1 isoform encoded by TUBB1 as indicated in figures 1 C and D. This region is positioned away from the dimer:dimer interface, and the C-terminal tail is an established site for post-translational modification (PTM), partic- in the TUBB1 gene within 6 base pairs of one another. The first, family A, is comprised of 3 individuals, two of whom carry an Arginine to Tryptophan (p.R359W) coding mutation. Interestingly, all 3 individuals in family A harbour a GFI1B mutation. However, the individuals with the reported TUBB1 mutation (A:1 and A:3) present with a macrothrombocytopenia and high IPF, while the patient without the R359W TUBB1 mutation presented with a normal platelet count. The second family is comprised of a single individual, recently deceased, with a frameshift mutation 6 base pairs from the missense reported in family A. In this individual's case, the insertion of a guanine nucleotide results in a frameshift with a premature stop codon 19 amino acids from the leucine to alanine change. (C) The C-terminal tail is downstream of both mutations in these families, and projects away from the dimer:dimer interface. The C-terminal sequence of TUBB1 is rich in glutamate residues which can be targeted for polymodification. (D) Based on homology modelling of TUBB1, we predict that the missense mutation reported in family A is likely to affect the fold of the C-terminal tail, while the frameshift causes a truncation of this region. (E) The arginine residue mutated in family A is highly conserved across species, as are sequences adjacent to the frameshift in patient B.
ularly as it is rich in glutamate residues which are known targets for glutamylation and glycylation (1) (Figure 1 C,D) . Both affected TUBB1 sequence variants are highly conserved in mammals (Figure 1 E) . We predicted that the R359W missense substitution is likely to alter the folding of the Cterminal tail, potentially affecting PTM or interactions with critical microtubule accessory proteins (MAPs) (Figure 1  C,D) . Similarly the G insertion and subsequent frameshift are likely to truncate the C-terminal region.
Patient platelet function was investigated using flow cytometry due to the reduced platelet count observed. Patient B demonstrated a significant reduction in surface P-selectin and fibrinogen uptake in response to all agonists ( Figure S1 ). Family A showed no change in the levels of surface receptor expression, but showed weak P-selectin and fibrinogen responses when activated with a low concentration ADP, CRP, and PAR-1, suggesting a mild secretion defect ( Figure S1 C,D).
Patients with C-terminal variants in this study and others previously reported by Fiore et al. phenocopy individuals with a complete loss of the -1 tubulin (18) (19) (20) , suggesting that the C-terminal tail is likely critical to the function of TUBB1 in the myriad complex roles of microtubules in both MKs and platelets. As this C-terminal tail is rich in glutamate residues which are often targeted for polymodification, we began to investigate the role of polyglutamylation and polyglycylation in human stem cell derived megakaryocytes and healthy donor platelets.
iPSC-derived proplatelet forming MKs are both polyglycylated and polyglutamylated. Polyglutamylation has recently been reported in a modified CHO cell line and human platelets, however no evidence of this PTM has been reported in human MKs. A species dependent variation in the expression of modifying enzymes has been reported and discussed, therefore a human model is required to investigate the role of this polymodification in platelet production (25, 30, 31) . To date, polyglycylation has not been reported in either platelets or megakaryocytes, however both modifications target the same glutamate residues, suggesting a potentially competitive mechanism by which these PTMs are applied to -1 tubulin.
To investigate polymodification in human megakaryocytes, we adapted a directed differentiation protocol previously reported by Feng et al. to generate large populations of mature, proplatelet forming cells (Supplementary Figure S2 ). Cells were differentiated and stained for CD42b as a marker for mature, and hence TUBB1 expressing, MKs, and both polyglutamylated and polyglycylated tubulin. CD42b positive cells, including proplatelet forming cells, were also found to be positive for both polyglutamylated tubulin and polyglycylated tubulin (Figure 2 A. CRISPR knock-out of TUBB1 results in a complete loss of proplatelet formation. To date, the loss of TUBB1 has not been studied in human MKs. To interrogate the loss of the protein and its post-translational modifications, we generated an iPSC line with a bi-allelic loss of function mutations in the N-terminus of the coding region of TUBB1 ( Platelet activation results in the polyglutamylation of the marginal band. MKs and platelets both achieve markedly different morphologies and functions despite the expression of TUBB1 in both cell types. As such we hypotheized that the TUBB1 polymodifications evident in MKs might be differently regulated between resting and activated platelets. We therefore compared immunofluorescence stain- ing of polyglutamylated and polyglycylated tubulin between resting platelets and cells spread on fibrinogen and collagen. We found that resting platelets demonstrate a diffuse distribution of polyglutamylated tubulin which partially co-localises with the -tubulin marginal band. Interestingly however, we see a marked increase in the polyglutamylation of the marginal band on platelet activation and spreading on fibrinogen (**** p < 0.0001, *** p 0.003) (Figure 3 A) . Polyglycylated tubulin however, is observed as low-level, punctate staining throughout both resting and activated cells (Figure 3 B).
Western blotting of resting platelets and cells activated through exposure to collagen related peptide (CRP) over time does not show an increase in the total amount of polyglutamylated tubulin in the sample ( Figure 3C ). Interestingly, analysis of the co-localisation between -tubulin and polymodified residues shows a significant increase in co-localisation between polyglutamylated tubulin and the marginal band in both fibrinogen and collagen spread cells. No significant change in co-localisation is observed for polyglycylated residues (Figure 3 D) .
To investigate the distribution of both polyglutamylated and polyglycylated tubulin in the context of thrombi, platelets were activated in vitro using CRP and subsequently fixed and mounted on to Poly-L-Lysine coated coverslips. These cells were then stained for both -tubulin and polyglutamylated or polyglycylated tubulin respectively (Figure 3 F,G) . Interestingly, polyglutamylated tubulin is evident throughout the aggregate on the marginal band of platelets, while polyglycylated tubulin is diffusely distributed (Figure 3 F,G ).
Acetylation and tyrosination have been previously reported in platelets, however their role in maintaining the marginal band and/or driving morphological change on platelet activation remains unclear (13) . To determine whether the polyglutamylation of the marginal band we observe thus far coincides with these PTMs, we performed a time course of spreading on fibrinogen to determine whether there is an equivalent increase in either acetylation or tyrosination of the marginal band. Interestingly, we find no marked acetylation or tyrosination of this structure over the time course, while a notable polyglutamylation of the marginal band is evident from the earliest time point (10 minutes spreading on fibrinogen) (Figure 3 H, I ).
MK and platelet polymodification is regulated through the expression of both modifying and reversing enzymes. Thus far we have reported a mechanism by which polyglutamylation and polyglycylation occur in mature and proplatelet forming MKs, followed by a change in distribution of these polymodifications (a reduction in polyglycylation) in the resting platelet, and finally an increase in the polyglutamylation of the marginal band on platelet activation and spreading. We hypothesise that the expression of cell specific subsets of effecting (Tubulin Tyrosine Like Ligase -TTLLs) and reversing (Cytoplasmic Carboxypeptidase -CCP) enzymes are required to achieve the observed regulation of these polymodifications. We designed a qRT-PCR panel to interrogate the expression of the 13 known mammalian TTLLs and 6 CCPs. We generated RNA from iPSC-MKs at different stages of the final terminal differentiation (Figures 4 A, S2A ). Day 1 (d1) cells are representative of a pool of haematopoeitic stem cells (HSCs) and MK progenitors, while day 5 (d5) cells are comprised of 60% CD41/42b+ cells (Figures 4 A, S2 E) . Finally, day 5 cells treated with heparin to induce proplatelet formation (d5 + Hep) were used to interrogate whether there is any specific up-regulation of TTLLs and/or CCPs on proplatelet formation (Figures 4 A, S2 D) . GAPDH housekeeping controls for each of the 3 samples (d1, d5, d5+Hep) show equivalent amplification of the housekeeping control, while results for TTLL family proteins show a number of enzymes expressed at different levels across the maturation of these cells (Figure 4 B,C) . Candidate TTLLs observed in the initial endpoint PCR were taken forward for quantification across replicates generated from multiple differentiations, which included TTLLs 1, 2, 3, 4, 5, 6, 7, 10, and 13 (Figure 4 C,D) . We find a significantly increased expression of TTLL1, TTLL2, TTLL4, and TTLL10 on proplatelet formation in cells treated with heparin (** p = 0.0081, * p = 0.0105, * p = 0.0260, *** p = 0.0004 respectively) (Figure 4 D) . CCP family enzymes were also found to be expressed in maturing MKs, notably CCP1, 3, 4, 5, and 6 (Figure 4 E) . Quantification across replicates revealed that CCP4 and 6 are upregulated on proplatelet production (* p = 0.0130, *** p = 0.0009) (Figure 4 F) .
To determine whether platelets demonstrate a difference in TTLL and CCP expression we repeated the qRT-PCR panel performed on maturing iPSC-MKs on platelet samples from 3 healthy donors. Each donor's platelets were either lysed in the resting state for RNA, or treated with CRP for 3 minutes to determine if there are changes in expression as a result of platelet activation. Interestingly, we found that none of the TTLLs and CCPs observed in iPSC MKs were consistently expressed across donors with the exception of TTLL7, a known polyglutamylase (Figure 4 I, complete gel in figure  S7 ). No differences between resting and activated platelets were observed (Figure 4 I ). This data shows a markedly different pattern of TTLL and CCP expression in both MKs and platelets, which correlates to the observed differences in polymodification.
TTLL10 variants cause higher MPV and moderate to severe bleeding in 3 unrelated families. Our qRT-PCR screen reveals that a number of TTLL and CCPs are upregulated during the process of platelet production, including the monoglycylase TTLL3 and the polyglycylase TTLL10. Three separate families were identified within the GAPP patient cohort with rare variants in the TTLL10 gene ( Figure  4J) . Two of the three variants result in frameshifts towards the N-terminus of the protein, preceding the ATP binding region (p.Pro15Argfs*38 and p.Val249Glyfs*57) ( Figure 4J ). The final family has a missense p.Arg340Trp variant. All three families report similar phenotypes, namely normal platelet counts, aggregation and secretion, but consistently high MPVs (normal ranges Mean Platelet Volume (fL) (7.83-10.5) and an established history of moderate to severe bleeding, including cutaneous bruising and menorrhagia ( Figure  4K ). Interestingly, one of the patients (A 1:1) was further studied, and on platelet spreading on fibrinogen we observe a marked increase in platelet area compared to controls ( Figure  4L ).
Platelet and MK polymodifications regulate motor protein localisation to drive both proplatelet formation and platelet shape change on activation. Thus far we have observed a markedly different distribution of polyglutamylated and polyglycylated residues in both human iPSCderived MKs and human donor peripheral blood platelets. Polyglutamylation has been reported as a means by which motor protein processivity is regulated, and like in neuronal cells, MK proplatelet formation is known to be driven by a mechanism of dynein mediated proplatelet sliding (32) . Similarly, the antagonistic movement of dynein and kinesin are known to maintain the marginal band in resting platelets (13) . We hypothesised that polyglutamylation in both MKs and platelets increases motor protein processivity. Therefore the polyglycylation evident in MKs (but notably absent in platelets) is likely a mechanism of regulating motor protein motility to prevent excessive polyglutamylation and control the microtubule sliding required for platelet production. Interestingly, the polyglutamylation and polyglycylation of proplatelet extensions is analogous to the polymodifications observed in ciliated cells, suggesting a potential role for axonemal dyneins in facilitating these unique cellular processes. To test this hypothesis, we first performed a time course of platelet spreading on fibrinogen and measured co-localisation between polyglutamylated tubulin and axonemal dynein (DNAL1 -axonemal light chain 1). We observe a sharp loss of co-localisation between axonemal dynein and polyglutamylated residues upon platelet spreading (Figure 5 A,B) . induce proplatelet formation (d5 + Hep) were used to determine whether an upregulation of these enzymes is evident on platelet production. (B) Samples were amplified with housekeeping GAPDH primers to ensure that any differences in TTLL or CCP expression observed were not due to differences in RNA abundance or quality. (C) A number of TTLL family enzymes were observed, including TTLLs1, 2, 3, 4, 5, 6, 7, 10, and 13. Of these, a number appeared to be up-regulated in mature and proplatelet forming cells. (D) These samples were taken forward and expression was quantified over multiple differentiations using the ""CT method using d1 cells as controls to determine if there was any upregulation in TTLL expression on platelet production. TTLL 1, 2, 4, and 10 expression was found to be significantly upregulated on treatment with heparin (** p = 0.0081, * p = 0.0105, * p = 0.0260, *** p = 0.0004 respectively). (E) A similar panel was performed on CCP enzymes which reverse polymodifications, with expression of CCP1, 3, 4, 5, and 6 was observed. (F) Statistically significant upregulation of CCPs 4, and 6 were observed on proplatelet production (* p = 0.0130, *** p = 0.0009). (G) In resting (-) and CRP activated (+) platelets from 3 healthy donors TTLL7 was the only modifying enzyme found to be consistently expressed. (J) Three unrelated families were identified within the GAPP cohort, two with frameshift truncations and one with a missense (p.Pro15Argfs*38, p.Val249Glyfs*57, and p.Arg340Trp respectively). Interestingly, axonemal dynein is also localised towards the leading edge of platelets when spread on fibrinogen ( Figure  5A ). This data suggests that the increased polyglutamylation of the marginal band observed on platelet spreading drives an outward movement of axonemal dynein. To confirm the role of axonemal dynein specifically in this process, we also stained spreading platelets for cytoplasmic dynein and observe a central distribution, suggesting an alternative role for cytoplasmic dynein in platelets ( Figure S4 ).
To confirm that the loss of co-localisation observed was spe- cific to polyglutamylated residues, we co-stained resting and spread platelets (fibrinogen and collagen) for both polyglutamylated and polyglycylated tubulin and compared their co-localisation with dynein and kinesin-1, a motor protein recently reported to be important in platelet secretion (33) . We found that while in both fibrinogen and collagen spread platelets a leading edge distribution of axonemal dynein is evident ( Figure 5 ) which poorly co-localises with polyglutamylated tubulin, there is no particular spatial relationship between polygylcylated tubulin and axonemal dynein ( Interestingly, kinesin-1 is evident throughout the spread platelet, and while there is a significant decrease in the co-localisation of this motor with polyglutamylated tubulin, there is no change in co-localisation between the polyglycylated residues and kinesin-1 (Figure 5 F,G,H) . This data suggests that polyglutamylated tubulin accelerates motor protein motility as previously described in vitro assays, while polyglycylation potentially acts as a 'braking' mechanism.
In proplatelet extensions axonemal dynein and kinesin-1 are both evident along the length of the proplatelet shaft (Figure 5 I) . A mechanism of dynein mediated sliding has been reported as the driver of proplatelet elongation, however the original work cites cytoplasmic dynein as the mediator of this effect (32) . Evidence of axonemal dynein in both the platelet and the proplatelet extension suggests that axonemal dynein likely plays a role in this process. TUBB1 knock-out cells show no proplatelet formation, and a significant reduction in the colocalisation of dynein with polyglutamyulated residues when compared to wild type iPSC-MKs ( Figure 5K ).
Discussion
Platelets and their progenitor cells, megakaryocytes, are a unique model for the study of the tubulin code. Like other specialist cells, they both express a lineage restricted isoform of -tubulin (TUBB1) which is linked to disease pathologies when lost (inherited macrothrombocytopenias) (5, (18) (19) (20) . However, unlike other specialist cells which exemplify the tubulin code, MKs and platelets execute markedly different functions despite their shared -1 tubulin. MKs are the largest cell of the bone marrow, typified by a lobed, polyploid nucleus and the generation of long proplatelet extensions into the bone marrow sinusoids for the generation of platelets. Conversely platelets themselves are anucleate and the smallest circulating component of peripheral blood, classically involved in haemostasis and thrombosis, but with a myriad of other roles in wound healing, inflammation, and cancer progression. A key question is therefore how TUBB1, restricted to both cell types, helps these cells achieve markedly different morphologies and functions. We hypothesised that a system of polymodification (polyglutamylation and polyglycylation) targeting the glutamate rich C-terminus of thistubulin isoform, analogous to similar post-translational modifications demonstrated in cilia and neuronal cells, is a likely mechanism by which the interactions of -1 tubulin with key motors are regulated in both MKs and platelets. The study of this system is complicated by a lack of human cell lines which phenocopy primary MKs, namely in the generation of proplatelet extensions. Recent advances in the generation of MKs from iPSCs have allowed for the generation of large pools of mature CD41/42b+ cells, however few of these approaches have yielded large populations of MKs forming proplatelet networks equivalent to those produced by murine foetal liver cells (34, 35) . In the study of the tubulin code and a system of post-translational modification, a species specific model is needed due to controversies regarding the functionality of particular modifying enzymes. TTLL10 for example, has both been reported as functionally redundant in humans by Rogowski et al., and as an 'elongase' requiring the expression of an initiating enzyme (TTLL3) to enact its function as a polyglycylase (25, 28, 36) . Therefore in this work we adapt an existing method of directed differentiation to produce large, proplatelet producing samples of iPSC-MKs for extensive immunfluorescence analysis of polymodifications and their association with motor proteins. We report a system by which mature, CD42b+ iPSC-MKs demonstrate both polyglutamylation and polyglycylation. We do not observe any cells with proplatelet extensions lacking these polymodifications. Interestingly, we observe a markedly different distribution of these PTMs in the resting platelet, where polyglycylation is reduced and polyglutamylation is partially co-localised to the marginal band. On platelet activation, we observe a marked increase of polyglutamylation specific to the marginal band. In iPSC-MKs with CRISPR knock-out TUBB1, we see a complete loss of proplatelet formation and lose the distinct re-organisation of polyglutamylated and polyglycylated tubulin around the periphery of MKs as seen in wild type cells.
MK proplatelet extensions are known to be driven by a system of dynein mediated microtubule sliding, while the marginal band in a resting platelet has been shown to be maintained by the antagonistic movement of dynein and kinesin (13, 14, 32) . Interestingly, polyglutamylation has been reported as a mechanism of altering motor protein processivity, with in vitro assays suggesting that polyglutamylation of -tubulin isoforms like TUBB1 and TUBB3 accelerates these motors (29) . We show a significant effect of polyglutamylation on the spatial localisation of dynein and kinesin, one which is not evidenced by polyglycylated residues, supporting in vitro assays which suggest that polyglutamylation is an accelerator of motor proteins. Our data suggests that polyglycylation does not have such an effect on motor protein processivity. As both polyglutamylation and polyglycylation target the same substrate (a tubulin tail glutamate residue), it is likely that the competitive modification of these residues allows for the tight regulation of motor protein motility needed for proplatelet elongation. Interestingly, the re-distribution of platelet polyglutamylation to the marginal band on platelet activation suggests that this is the mechanism by which the delicate balance of antagonistic motor protein function required to maintain the marginal band is disrupted.
This system of competitive polymodification is analogous to the post-translational modification of ciliated cells, and so we reasoned that axonemal dynein, an isoform of the motor exclusive to axonemes, may play a role in both platelet formation and activation (6, 37, 38) . We find evidence of axonemal dynein on both proplatelet extensions and at the leading edge of spreading platelets. To our knowledge this is the first evidence of a functional role of axonemal dynein outside of classical ciliated structures. In our TUBB1 knock-out MKs, we observe a decrease in the colocalisation of dynein to polyglutamyulated tubulin, suggesting that the loss of proplatelet formation observed in these cells is due to a dysregulation of the dynein-mediated microtubule sliding known to drive the elongation of the proplatelet shaft (32) .
Our data suggests a tightly regulated, reversible system of polymodification which must be mediated by the cell specific expression of TTLLs and CCPs. Our expression profiles show a number of TTLLs and CCPs are expressed by MKs, while only the polyglutamylase TTLL7 is expressed by platelets, consistent with our finding that in the platelet activation results in polyglutamylation of the marginal band, but no change in polyglycylation. In MKs we find an increase in expression of two TTLLs known to be involved in glycylation -the initiase TTLL3 and the elongase TTLL10. As previously mentioned, TTLL10 is the source of some controversy in the field, with reports suggesting the acquisition of a mutation in humans which renders the enzyme non-functional. Our findings support a role of TTLL10 as a polyglycylase on co-expression with TTLL3 as reported by Ikegami et al. in cell lines through co-transfection experiments. In mice with a variant of the deglutamylase CCP1, an increase in polyglutamylation results in the degeneration of photoreceptors in the retina (39) . A series of human mutations in the deglutamylase CCP5 have been reported in patients with visual impairments (40, 41) . A loss of glycylation has similarly been reported to affect ciliary function and length in mice, and a loss of this PTM in photoreceptors results in ciliary shortening and subsequent retinal degeneration in mouse models (8, 42) . A knock-out model of TTLL3 results in a loss of glycylation and the development of tumours in the colon (43) . In the absence of established TTLL and TUBB1 specific inhibitors, the role of the PTM of TUBB1 in human physiology is best understood by disease models, and much of our current understanding of the tubulin code is derived from correlating the loss of PTMs with human pathologies (5). We identify two unrelated families with C-terminally oriented TUBB1 variants, both presenting with macrothrombocytopenia and supporting a report from Fiore et al. suggesting that the loss of the C-terminus is causative of the disease. TTLLs are generally, ubiquitously expressed and extensively required for the development of neuronal, retinal, and ciliated cells. For the first time, we identify 3 unrelated families with TTLL10 variants which result in an increase in platelet volume and an established history of bleeding and provides an invaluable insight to the potential role of polyglycylation in the context of platelet production and function. Our data suggests shows that both TTLL3 and TTLL10 are expressed in platelet producing MKs. Our patient cohort do not lose TTLL3 function, and as such the action of TTLL3 as an initiase will occupy glutamate residues which would otherwise be polyglutamylated. In these patients we likely see a loss of polyglycylation, but no co-incident increase in polyglutamylation due to the action of the initiase (TTLL3). As polyglutamylation and monoglycylation are unaffected, platelet counts (and production) are normal, however, affected individuals appear to have an increased platelet volume and bleeding, suggesting a role for the extended glycine tail in regulating platelet size, with a downstream effect on the ability of platelets to prevent bleeding.
Conclusions
The 'tubulin code' posits that a tightly regulated system of post-translational modification as well as the lineage restricted expression of tubulin isoforms is required to drive unique cellular behaviours. This has been shown through both human disease states and mouse models which demonstrate that the loss of cell specific isoforms or particular regulatory enzymes can result in a range of neuronal dysfunctions, ciliopathies, abnormal spermatogenesis (or sperm function), and platelet defects. The loss of TUBB1 has been established as causative of macrothrombocytopenias, however the mechanisms by which -1 tubulin achieves the distinctive morphologies and functions of both MKs and platelets remains elusive. Here we report a tightly regulated expression of glutamylating and glycylating enzymes through platelet production which drives the polyglutamylation and polyglycylation of MKs ( Figure 6 ). These modifications are reduced in the terminal platelet which only expresses the polyglutamylase TTLL7, and on activation the marginal band becomes heavily polyglutamylated to drive motor protein mediated shape change. We show a role for axonemal dynein in proplatelet extension and platelet spreading, and report novel variants of TTLL10 which result in bleeding through the loss of its' role as a polyglycylase. Ultimately the role of this system of polymodification is to fine tune the motility of motor proteins in both the MK and the platelet, allowing both cell types to achieve their unique functions. This work supports the paradigm of a 'tubulin code', and suggests that there is likely a complex regulatory system upstream of TTLLs and CCPs within an MK and a platelet which drives these PTMs.
Materials and Methods
Platelet preparation. Whole blood was obtained for each experiment from healthy volunteers under the University of Birmingham's ERN 11-0175 license 'The regulation of activation of platelets'. Volumes of 25 mL were drawn from volunteers into sodium citrate. PRP (platelet-rich plasma) was generated by centrifugation of samples for 20 minutes at 200g. PRP was further spun to isolate platelets by centrifugation at 1,000g for 10 minutes with prostacyclin (0.1 µg/mL) and ACD. The resulting pellet was suspended in Tyrode's buffer prepared fresh, and pre-warmed at 37 0 C (5mM glucose, 1mM MgCl2, 20mM HEPES, 12mM NaHCO3, 2.9 mM KCL, 0.34mM Na2HpO4, 129mM NaCl to a pH of 7.3). This suspension was spun again at 1,000g with prostacyclin at the same concentration before re-suspended to a final concentration of 2 x 10 8 /mL. Platelets were left to rest for 30 minutes at room temperature before any further processing or treatment.
Platelet spreading. Resting platelets were fixed by preparing platelets at a concentration of 4 x 10 7 /mL and mixing with equal volumes of 10% neutral buffered Formalin in a 15mL falcon tube. This mixture was inverted gently to mix the sample, and left to incubate for 5 minutes before subsequently adding 300µL of the resulting fixed, resting platelets to coverslips coated in Poly-L-Lysine (Sigma). Cells were then spun down at 200g for 10 minutes. Spreading was performed on human fibrinogen (Plasminogen, von Willebrand Factor and Fibronectin depleted -Enzyme Research Laboratories) and Horm collagen (Takeda). Coverslips were coated overnight at a concentration of 100 µg and 10µg/mL (fibrinogen and collagen) respectively, before blocking for 1 hour in denatured fatty acid free 1% BSA (Life Technologies). Finally coverslips were washed once with PBS before the addition of platelets. Unless other- Fig. 6 . A system of competitive polymodification of TUBB1 driven by the expression of TTLL and CCP enzymes is required for platelet production and function. We observe a system by which as iPSC-MKs mature and express TUBB1, they acquire both polyglutamylated and polyglycylated tubulin which co-incides with an increase in the expression of glutamylating and glycylating TTLLs and reversing CCPs. A resting platelet is partially polyglutamylated, and on activation the marginal band is polyglutamylated to drive shape change and spreading throguh the action of TTLL7.
wise stated (as in the time course experiment), platelets were spread for 45 minutes at 37 0 C. Fixation for spread platelets was performed in formalin as for resting platelets for 10 minutes.
Immunofluorescence. After fixation platelets were washed twice with PBS before incubation in 0.1% Triton X-100 for 5 minutes. The subsequently permeabilised cells were washed twice with PBS before blocking in 2% Goat serum (Life Technologies) and 1% BSA (Sigma). Fixed, permeablised, and blocked cells were then incubated with primary antibodies at a concentration of 1:500 unless otherwise stated. The following antibodies were used for experiments in this work: polyglutamylated tubulin (mouse monoclonal antibody, clone B3 T9822, Sigma), pan-polyglycylated antibody (mouse monoclonal antibody, AXO49, MABS276 Millipore), monoglycylated antibody (AXO 962 mouse monoclonal MABS277, EMD Millipore), kinesin-1 (rabbit monoclonal to KIF1B ab 167429, abcam), axonemal dynein, -tubulin (Rabbit polyclonal PA5-16863), tyrosinated tubulin (rabbit monoclonal antibody, clone YL1/2, MAB1864, EMD Millipore), acetylated tubulin (Lys40, 6-11B-1, mouse monoclonal antibody, Cell Signalling Technology). DNAL1 antibody (PA5-30643 Invitrogen). After a 1 hour incubation in the relevant mix of primary antibodies. Cells were washed twice with PBS before incubation in secondary antibodies (Alexa-568-phalloidin, antirabbit Alexa-647, anti-mouse Alexa-588) for one hour at a dilution of 1:300 in PBS.
Stem Cell Culture. Gibco human episomal induced pluripotent stem cell line was purchased from Thermo Scientific and cultured on Geltrex basement membrane in StemFlex medium (Thermo Scientific). Routine passaging was performed using EDTA (Sigma), with single cell seeding performed for transfection and attempted clonal isolation through the use of TryplE (Thermo Scientific). Briefly, cells were washed twice with PBS and once with either EDTA (for clump passaging) or TrypLE (for single cell) before incubation in 1mL relevant detachment media for 3 minutes at 37 ¶ C. For clump passaging, EDTA was removed and 1mL of StemFlex added. Cells were detached by triurtating media onto the bottom of the well and subsequently adding the required volume to fresh media (in a new, GelTrex coated plate). For single cell seeding, TrypLE was diluted in 2mL StemFlex and the solution added to a 15mL falcon tube for centrifugation at 200g for 4 minutes. The supernatant was then discarded and the cell pellet resuspended in the required volume.
iPSC MK differentiation. iPSC differentiation to mature, proplatelet forming megakaryocytes was performed using a protocol based on work published by Feng et al. (35) . To summarise, cells were detached by clump passaging and seeded on dishes coated with Collagen Type IV (Advanced Biomatrix) at 5µg/cm 2 . Cells were seeded overnight with RevitaCell to support survival on the new basement substrate. To begin the protocol cells were washed twice and incubated in phase I medium comprised of APELII medium (Stem Cell Technologies) supplemented with BMP-4 (Thermo Scientific), FGF--, and VEGF (Stem Cell Technologies) at 50ng/mL each. Cells were incubated at 5% oxygen for the first four days of the protocol before being placed in a standard cell culture incubator for a further two days in freshly made phase I medium. At day 6 of the protocol cells were incubated in phase II media comprised of APELII, TPO (25 ng/mL), SCF (25 ng/mL), Flt-3 (25ng/mL), Interleukin-3 (10ng/mL), Interleukin-6 (10 ng/mL) and Heparin (5 U/mL) (all supplied by Stem Cell Technologies). Each day in phase II media suspension cells were spun down at 400g for 5 minutes and frozen in 10% FBS/DMSO. After 5 days of collection, all frozen cells were thawed for terminal differentiation. Terminal differentiation was performed by incubating cells in StemSpan II with heparin (5U/mL) and Stem Cell Technologies Megakaryocyte Expansion supplement on low attachment dishes (Corning).
RNP Complexes.
The IDT Alt-R®RNP system was used for the relevant experiments in this chapter. crRNAs were ordered at 2nmol (following the design of TubA1B targeting guide C reported in Chapter 2) and resuspended in 20µL TE buffer (IDT) for a final concentration of 100µM. Atto-555 labelled tracrRNAs were ordered at 5nmol and resuspended in a volume of 50µL for a final concentration of 100µM. To prepare small guide RNAs (sgRNA), equimolar ratios of both crRNA and tracrRNA were mixed with Nuclease Free Duplex Buffer (IDT). This mix was then incubated at 95 ¶ C for 5 minutes before allowing the reaction mix to cool at -1 ¶ C/second to 25 ¶ C. This mix was then spun down and complexed with either HiFi Cas9 V3 (1081058 -IDT) or Cas9 R10A nickase (1081063 -IDT) purified Alt-R®. Cas9 protein was diluted to 6µg per transfection and incubated with an equal volume of annealed sgRNA. This mix was left for 30 minutes at room temperature to form complete and stable RNP complexes.
Stem Cell Transfection. iPSC transfection was performed using Lipofectamine Stem according to manufacturer instructions. Briefly, iPSC were seeded on 24 well dishes coated with Geltrex at 50,000 cells per well. After an overnight incubation in StemFlex with RevitaCell, cells were washed twice with PBS and once with OptiMem before incubation in OptiMem with RevitaCell. RNP complexes were prepared as described in section A and resuspended in 25µL OptiMem per reaction. A Lipofectamine Stem master mix was prepared using 25µL OptiMem and 2µL Lipofectamine STEM per reaction (4µL if a donor template is included). Equal volumes of both Lipofectamine and RNP mix were incubated to form lipofection complexes over a 10 minute incubation at room temperature. The final transfection mix was added to cells in OptiMem and left for 4 hours before the addition of StemFlex medium (and any relevant small molecules). Measurement of iPSC transfection efficiency after treatment with Lipofectamine STEM and IDT RNP complexes was performed using manual cell counting in Evos acquired images (Phase contrast and fluorescence).
Microscopy. Images were acquired using an Axio Observer 7 inverted epifluorescence microscope (Carl Zeiss) with Definite Focus 2 autofocus, 63x 1.4 NA oil immersion objective lens, Colibri 7 LED illumination source, Hammamatsu Flash 4 V2 sCMOS camera, Filter sets 38, 45HQ and 50 for Alexa488, Alexa568 and Alexa647 respectively and DIC optics. LED power and exposure time were chosen as appropriate for each set of samples but kept the same within each experiment. Using Zen 2.3 Pro software, five images were taken per replicate, either as individual planes (spread platelets) or representative Z-stacks (resting platelets).
Image and statistical analysis. Statistical analysis was performed using GraphPad PRISM 7. Image analysis was performed using a customed workflow. Briefly, the actin channel from resting and spread platelet images was used to train Ilastik pixel classifiers (approximately 6 images per condition) for segmentation based on this channel. This was incorporated into a KNIME workflow which would run images through the classifier to generated segmented binaries in which co-localisation and fluorescence intensity statistics were calculated (44, 45) . For the data presented in this manuscript, M 1 dif f (a corrected Mander's co-efficient to channel 1) was used to determine the co-localisation of PTMs to tubulin, and an M 2 dif f value (corrected Mander's co-efficient to channel 2) was used to calculate the colocalisation of motor proteins to PTMs of interest (46) .
Quantitative Real Time PCR (qRT-PCR).
To determine whether the 13 mammalian TTLLs and 6 CCPs were expressed in iPSC-MKs at the different stages of differentiation (day 1, day 5 and day 5 +heparin) a qRT-PCR panel was developed using TaqMan technology and an ABI 7900 HT analyser (Applied Biosystems, Warrington, UK). RNA samples were isolated and reverse-transcribed and amplified with the relevant primers using SYBR-Green based technology (Power SYBR(r) Master Mix, Life Technologies). Total RNA was extracted from iPSC cells using the NucleoSpin RNA kit (Machery-Nagel) and cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies). qRT-PCR was performed on all the TTLL/CCP fragments generated from primers designed in table x and the housekeeping control GAPDH (GAPDHFOR 5 Õ ≠ GAAGGT GAAGGT CGGAGT ≠ 3 Õ and GAPDHREV 5 Õ GAAGAT GGT GAT GGGAT T T C ≠ 3 Õ ). Each reaction was set up in triplicate including a nontemplate control. Expression was analysed using the CT method using D1 undifferentiated cells as a control. A full list of primer sequences has been uploaded as figure S5.
TUBB1 Homology Modelling. Homology models of TUBB1 WT and mutations were made using SWISS MODEL software (? ? ? ? ), using the solved TUBB3 heterodimer as a template (PDB: 5IJ0 (? )). TUBB1 and TUBB3 share approximately 80% sequence identity, and the model created corresponds to residues 1-425 of TUBB1.
